Publicly traded biotechnology company (Nasdaq: FRNM)
Appears in 2 stories · Last updated Sep 30, 2026
As of September 2026: Developer and manufacturer of SimpleScreen CRC; receives milestone payments tied to commercial performance
Abbott began selling SimpleScreen CRC on September 30, giving average-risk Americans 45 and older a second FDA-approved blood test for colorectal cancer screening. The test reads cell-free DNA from a simple blood draw for signals associated with cancer. Abbott is betting it reaches people who never complete a colonoscopy or stool test.
Updated Sep 30
As of August 2026: Won FDA breakthrough status for its lung cancer blood test
Today, catching lung cancer early usually means a CT scan of your chest. Fewer than one in five people who qualify actually get one. On August 12, 2026, the FDA gave Freenome's blood test for lung cancer a status meant to speed its review, betting that a simple blood draw could reach the millions who skip the scan.
Updated Aug 13
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
